Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Authors
Nutting, CMorden, J
Harrington, K
Urbano, Teresa G
Bhide, S A
Clark, C
Miles, E A
Miah, A B
Newbold, K
Tanay, M A
Adab, Fawzi
Jefferies, S J
Scrase, C
Yap, Beng K
A'Hern, R
Sydenham, M A
Emson, M
Hall, E
Affiliation
Head and Neck Unit, Royal Marsden Hospitals NHS Foundation Trust, London, UK.Issue Date
2011-02
Metadata
Show full item recordAbstract
Xerostomia is the most common late side-effect of radiotherapy to the head and neck. Compared with conventional radiotherapy, intensity-modulated radiotherapy (IMRT) can reduce irradiation of the parotid glands. We assessed the hypothesis that parotid-sparing IMRT reduces the incidence of severe xerostomia.Citation
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. 2011, 12 (2):127-36 Lancet Oncol.Journal
Lancet OncologyDOI
10.1016/S1470-2045(10)70290-4PubMed ID
21236730Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(10)70290-4